In colorectal cancer, METTL3 expression was found to be much higher in patients with higher FDG uptake, promoting cancer progression, which depends on cell glycolytic metabolism, by stabilizing HK2 and GLUT1 expression in an m6A-IGF2BP2/3-dependent manner [23]. Here, METTL3 is linked to colorectal cancer.